
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS. ROSUVASTATIN tablets, for oral use Initial U.S. Approval: 2003 RECENT MAJOR CHANGES Dosage and Administration Modifications Due to Drug Interactions (2.6) 07/2023 Contraindications, Pregnancy and Lactation (4) Removed 01/2023 Warnings and Precautions (5.2) 01/2023 Warnings and Precautions, Concomitant Coumarin Anticoagulants (5.4) Removed 01/2023 INDICATIONS AND USAGE Rosuvastatin tablets are an HMG Co-A reductase inhibitor (statin) indicated: (1) • To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults

- To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥ 2 mg/L, and at least one additional CV risk factor.
- As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
- As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults.
- As an adjunct to diet to reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
- As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).
- As an adjunct to diet for the treatment of adults with:
 - Primary dysbetalipoproteinemia.
 - Hypertriglyceridemia.

DOSAGE AND ADMINISTRATION
Take orally with or without food, at any time of day. (2.1)
Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust dosage if necessary. (2.1)
Adults: Recommended dosage range is 5 to 40 mg once daily. (2.1)
<i>Pediatric Patients with HeFH</i> : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. (2.2) <i>Pediatric Patients with HoFH</i> : Recommended dosage is 20 mg once daily for patients aged 7 years and
older. (2.2)
Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. (2.4)
Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. (2.5, 5.1, 8.6)
See full prescribing information for rosuvastatin tablets dosage and administration modifications due to drug interactions. (2.6)
DOSAGE FORMS AND STRENGTHS
Tablets: 5 mg, 10 mg, 20 mg, and 40 mg of rosuvastatin. (3)
CONTRAINDICATIONS
Acute liver failure or decompensated cirrhosis. (4)
Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. (4)

------ WARNINGS AND PRECAUTIONS ------

• *Myopathy and Rhabdomyolysis*: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher rosuvastatin dosage. Asian patients may be at higher risk for myopathy. Discontinue rosuvastatin if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue rosuvastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing rosuvastatin dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. (5.1, 7.1, 8.5, 8.6, 8.8)

- *Immune-Mediated Necrotizing Myopathy (IMNM)*: Rare reports of IMNM, an autoimmune myopathy, have been reported with statin use. Discontinue rosuvastatin if IMNM is suspected. (5.2)
- *Hepatic Dysfunction*: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue rosuvastatin. (4, 5.3, 8.7)

Most frequest adverse reactions (rate \geq 2%) are headache, myalgia, abdominal pain, asthenia, and nausea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Biocon Pharma Inc. at 1-866-924-6266 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full prescribing information for details regarding concomitant use of rosuvastatin with other drugs that increase the risk of myopathy and rhabdomyolysis. (2.6, 7.1)

Aluminum and Magnesium Hydroxide Combination Antacids: Administer rosuvastatin at least 2 hours after the antacid. (2.6, 7.2)

Wafarin: Obtain INR prior to starting rosuvastatin. Monitor INR frequently until stable upon initiation, dose titration or discontinuation. (7.3)

USE IN SPECIFIC POPULATIONS

- Pregnancy: May cause fetal harm. (8.1)
- Lactation: Breastfeeding not recommended during treatment with rosuvastatin. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 9/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 General Dosage and Administration Information
- 2.2 Recommended Dosage in Adult Patients
- 2.3 Recommended Dosage in Pediatric Patients
- 2.4 Dosing in Asian Patients
- 2.5 Recommended Dosage in Patients with Renal Impairment
- 2.6 Dosage and Administration Modifications Due to Drug Interactions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Myopathy and Rhabdomyolysis
- 5.2 Immune-Mediated Necrotizing Myopathy
- 5.3 Hepatic Dysfunction
- 5.4 Proteinuria and Hematuria
- 5.5 Increases in HbA1c and Fasting Serum Glucose Levels

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin

7.2 Drug Interactions that Decrease the Efficacy of Rosuvastatin

7.3 Rosuvastatin Effects on Other Drugs

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment
- 8.8 Asian Patients
- **10 OVERDOSAGE**

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics
- 12.5 Pharmacogenomics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Rosuvastatin tablets are indicated:

- To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor.
- As an adjunct to diet to:
 - Reduce LDL-C in adults with primary hyperlipidemia.
 - Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults.
 - Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
- As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).
- As an adjunct to diet for the treatment of adults with:
 - Primary dysbetalipoproteinemia.
 - Hypertriglyceridemia.

2 DOSAGE AND ADMINISTRATION

2.1 General Dosage and Administration Information

- Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. The tablet should be swallowed whole.
- Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust the dosage if necessary.
- If a dose is missed, advise patients not take an extra dose. Resume treatment with the next dose.

2.2 Recommended Dosage in Adult Patients

- The dosage range for rosuvastatin tablets are 5 to 40 mg orally once daily.
- The recommended dose of rosuvastatin tablets depends on a patient's indication for usage, LDL-C, and individual risk for cardiovascular events.

2.3 Recommended Dosage in Pediatric Patients

Dosage in Pediatric Patients 8 Years of Age and Older with HeFH

The recommended dosage range is 5 mg to 10 mg orally once daily in patients aged 8 years to less than 10 years and 5 mg to 20 mg orally once daily in patients aged 10 years and older.

Dosage in Pediatric Patients 7 Years of Age and Older with HoFH

The recommended dosage is 20 mg orally once daily.

2.4 Dosing in Asian Patients

Initiate rosuvastatin tablets at 5 mg once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits of rosuvastatin tablets when treating Asian patients not adequately controlled at doses up to 20 mg once *daily* [see Warnings and Precautions (5.1), Use in Specific Populations (8.8), and Clinical Pharmacology (12.3)].

2.5 Recommended Dosage in Patients with Renal Impairment

In patients with severe renal impairment (CLcr less than 30 mL/min/1.73 m2) not on hemodialysis, the recommended starting dosage is 5 mg once daily and should not exceed 10 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].

There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.

2.6 Dosage and Administration Modifications Due to Drug Interactions

Rosuvastatin Tablets Dosage Modifications Due to Drug Interactions

Table 1 displays dosage modifications for rosuvastatin tablets due to drug interactions *[see Warnings and Precautions (5.1) and Drug Interactions (7.1)]*.

Table 1: Rosuvastatin Tablets Dosage Modifications Due to Drug Interactions

Concomitantly Used Drug	Rosuvastatin Dosage Modifications
Cyclosporine	Do not exceed 5 mg once daily.
Teriflunomide	Do not exceed 10 mg once daily.
Enasidenib	Do not exceed 10 mg once daily.

Capmatinib	Do not exceed 10 mg once daily.
Fostamatinib	Do not exceed 20 mg once daily.
Febuxostat	Do not exceed 20 mg once daily.
Gemfibrozil	Avoid concomitant use. If used
	concomitantly, initiate at 5 mg once
	daily and do not exceed 10 mg once daily.
Tafamidis	Avoid concomitant use. If used
	concomitantly, initiate at 5 mg once
	daily and do not exceed 20 mg once daily.
Antiviral Medications	
	Concomitant use not
	recommended.
 Sofbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir 	
	Initiate at 5 mg once daily. Do not
	exceed 10 mg once daily.
 Simeprevir Das abuvir (ambitas) vir (paritaprovir (ritapa) vir 	
 Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/Grazoprevir 	
 Sofosbuvir/Velpatasvir 	
 Glecaprevir/Pibrentasvir 	
 Atazanavir/Ritonavir 	
 Lopinavir/Ritonavir 	
Darolutamide	Do not exceed 5 mg once daily.
Regorafenib	Do not exceed 10 mg once daily.

Rosuvastatin Tablets Administration Modifications Due to Drug Interactions

When taking rosuvastatin tablets with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin tablets at least 2 hours before the antacid [see Drug Interactions (7.2)].

3 DOSAGE FORMS AND STRENGTHS

- 5 mg: Yellow, round, biconvex, film-coated tablets, debossed with '5' on one side and 'B' on other side.
- 10 mg: Pink, round, biconvex, film-coated tablets, debossed with '10' on one side and 'B' on other side.
- 20 mg: Pink, round, biconvex, film-coated tablets, debossed with '20' on one side and 'B' on other side.
- 40 mg: Pink, oval, biconvex, film-coated tablets, debossed with '40' on one side and 'B' on other side.

4 CONTRAINDICATIONS

Rosuvastatin tablets are contraindicated in the following conditions:

• Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].

• Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets [see Adverse Reactions (6.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Myopathy and Rhabdomyolysis

Rosuvastatin tablets may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis with statins, including rosuvastatin tablets.

Risk Factors for Myopathy

Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipidlowering therapies), and higher rosuvastatin tablets dosage. Asian patients on rosuvastatin tablets may be at higher risk for myopathy [see Drug Interactions (7.1) and Use in Specific Populations (8.8)]. The myopathy risk is greater in patients taking rosuvastatin tablets 40 mg daily compared with lower rosuvastatin tablets dosages.

Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis

The concomitant use of rosuvastatin tablets with cyclosporine or gemfibrozil is not recommended. Rosuvastatin tablets dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [see Dosage and Administration (2.6)]. Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)].

Discontinue rosuvastatin tablets if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if rosuvastatin tablets is discontinued. Temporarily discontinue rosuvastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the rosuvastatin tablets dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

5.2 Immune-Mediated Necrotizing Myopathy

There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue rosuvastatin if IMNM is suspected.

5.3 Hepatic Dysfunction

Increases in serum transaminases have been reported with use of rosuvastatin [see

Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. In a pooled analysis of placebo-controlled trials, increases in serum transaminases to more than three times the ULN occurred in 1.1% of patients taking rosuvastatin versus 0.5% of patients treated with placebo. Marked persistent increases of hepatic transaminases have also occurred with rosuvastatin. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including rosuvastatin.

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Use in Specific Populations (8.7)].

Consider liver enzyme testing before rosuvastatin initiation and when clinically indicated thereafter. Rosuvastatin is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue rosuvastatin.

5.4 Proteinuria and Hematuria

In the rosuvastatin clinical trial program, dipstick-positive proteinuria and microscopic hematuria were observed among rosuvastatin treated patients. These findings were more frequent in patients taking rosuvastatin 40 mg, when compared to lower doses of rosuvastatin or comparator statins, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, consider a dose reduction for patients on rosuvastatin therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.

5.5 Increases in HbA1c and Fasting Serum Glucose Levels

Increases in HbA1c and fasting serum glucose levels have been reported with statins, including rosuvastatin. Based on clinical trial data with rosuvastatin, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus [see Adverse Reactions (6.1)]. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.

6 ADVERSE REACTIONS

The following important adverse reactions are described below and elsewhere in the labeling:

Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.1)]

Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions (5.2)]

Hepatic Dysfunction [see Warnings and Precautions (5.3)]

Proteinuria and Hematuria [see Warnings and Precautions (5.4)]

Increases in HbA1c and Fasting Serum Glucose Levels [see Warnings and Precautions (5.5)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse reactions reported in $\geq 2\%$ of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 2. These studies had a treatment duration of up to 12 weeks.

Adverse Reactions	Placebo N=382 %	Rosuvastatin 5 mg N=291 %	Rosuvastatin 10 mg N=283 %	Rosuvastatin 20 mg N=64 %		Total Rosuvastatin 5 mg-40 mg N=744 %
Headache	5.0	5.5	4.9	3.1	8.5	5.5
Nausea	3.1	3.8	3.5	6.3	0	3.4
Myalgia	1.3	3.1	2.1	6.3	1.9	2.8
Asthenia	2.6	2.4	3.2	4.7	0.9	2.7
Constipation	n 2.4	2.1	2.1	4.7	2.8	2.4

Table 2: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin and > Placebo in Placebo-Controlled Trials

Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. The following laboratory abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria; elevated creatine phosphokinase, transaminases, glucose, glutamyl transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities.

In the METEOR study, patients were treated with rosuvastatin 40 mg (n=700) or placebo (n=281) with a mean treatment duration of 1.7 years. Adverse reactions reported in \geq 2% of patients and at a rate greater than placebo are shown in Table 3.

Adverse Reactions	Placebo	Rosuvastatin 40 mg
	N=281	N=700
	%	%
Myalgia	12.1	12.7
Arthralgia	7.1	10.1
Headache	5.3	6.4
Dizziness	2.8	4.0
Increased CPK	0.7	2.6
Abdominal pain	1.8	2.4
ALT greater than 3x ULN ¹	0.7	2.2

Table 3: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin and > Placebo in the METEOR Trial

¹Frequency recorded as abnormal laboratory value.

In the JUPITER study, patients were treated with rosuvastatin 20 mg (n=8901) or placebo (n=8901) for a mean duration of 2 years. In JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with a HbA1c >6.5% at the end of the trial was significantly higher in rosuvastatin-treated versus placebo-treated patients [see Clinical Studies (14)]. Adverse reactions reported in \geq 2% of patients and at a rate greater than placebo are shown in Table 4.

Adverse Reactions	Placebo N=8901 %	Rosuvastatin 20 mg N=8901 %
Myalgia	6.6	7.6
Arthralgia	3.2	3.8
Constipation	3.0	3.3
Diabetes mellitus	2.3	2.8
Nausea	2.3	2.4

Table 4: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin and > Placebo in the JUPITER Trial

Pediatric Patients with HeFH

In a 12-week controlled study in pediatric patients 10 to 17 years of age with HeFH with rosuvastatin 5 to 20 mg daily *[see Use in Specific Populations (8.4) and Clinical Studies (14)]*, elevations in serum CK greater than 10 x ULN were observed more frequently in rosuvastatin-treated patients compared with patients receiving placebo. Four of 130 (3%) patients treated with rosuvastatin (2 treated with 10 mg and 2 treated with 20 mg) had increased CK greater than 10 x ULN, compared to 0 of 46 patients on placebo.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of rosuvastatin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood Disorders: thrombocytopenia

Hepatobiliary Disorders: hepatitis, jaundice, fatal and non-fatal hepatic failure

Musculoskeletal Disorders: arthralgia, rare reports of immune-mediated necrotizing myopathy associated with statin use

Nervous System Disorders: peripheral neuropathy, rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, and confusion) associated with the use of all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks). There have been rare reports of new-onset or exacerbation of myasthenia gravis, including ocular myasthenia, and reports of recurrence when the same or a different statin was administered.

Psychiatric Disorders: depression, sleep disorders (including insomnia and nightmares)

Reproductive System and Breast Disorders: gynecomastia

Respiratory Disorders: interstitial lung disease

Skin and Subcutaneous Tissue Disorders: drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug eruption

7 DRUG INTERACTIONS

7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin

Rosuvastatin is a substrate of CYP2C9 and transporters (such as OATP1B1, BCRP). Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. Table 5 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with rosuvastatin and instructions for preventing or managing them [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].

Table 5: Drug Interactions that Increase the Risk of Myopathy and
Rhabdomyolysis with Rosuvastatin

- · ·	
Cyclosporine	
Clinical Impact:	Cyclosporine increased rosuvastatin exposure 7-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with rosuvastatin.
Intervention:	If used concomitantly, do not exceed a dose of rosuvastatin 5 mg once daily.
Teriflunomide	
Clinical Impact:	Teriflunomide increased rosuvastatin exposure more than 2.5- fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.
Intervention:	In patients taking teriflunomide, do not exceed a dose of rosuvastatin 10 mg once daily.
Enasidenib	
	Enasidenib increased rosuvastatin exposure more than 2.4-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.
Intervention:	In patients taking enasidenib, do not exceed a dose of rosuvastatin 10 mg once daily.
Capmatinib	
Clinical Impact:	Capmatinib increased rosuvastatin exposure more than 2.1-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.
Intervention:	In patients taking capmatinib, do not exceed a dose of rosuvastatin 10 mg once daily.
Fostamatinib	
Clinical Impact:	Fostamatinib increased rosuvastatin exposure more than 2.0- fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.
Intervention:	In patients taking fostamatinib, do not exceed a dose of rosuvastatin 20 mg once daily.
Febuxostat	~ .
	Febuxostat increased rosuvastatin exposure more than 1.9-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.
Intervention:	In patients taking febuxostat, do not exceed a dose of rosuvastatin 20 mg once daily.
Gemfibrozil	

1	Comfibrazil cignificantly increased recurrentation	ovpacura and
	Gemfibrozil significantly increased rosuvastatin gemfibrozil may cause myopathy when given al	•
Clinical Impact:	myopathy and rhabdomyolysis is increased with	
	of gemfibrozil with rosuvastatin.	
	Avoid concomitant use of gemfibrozil with rosu	vastatin. If used
Intervention:	concomitantly, initiate rosuvastatin at 5 mg onc	
	exceed a dose of rosuvastatin 10 mg once daily	/.
Tafamidis		
	Tafamidis significantly increased rosuvastatin ex	posure and
Clinical Impact:	tafamidis may cause myopathy when given alor myopathy and rhabdomyolysis is increased with	ie. The risk of
	of tafamidis with rosuvastatin.	
	Avoid concomitant use of tafamidis with rosuva	statin. If used
	concomitantly, initiate rosuvastatin at 5 mg onc	
Intervention:	exceed a dose of rosuvastatin 20 mg once daily	
	signs of myopathy and rhabdomyolysis if used	concomitantly
	with rosuvastatin.	
Anti-Viral Medication		
Clinical Impact:	Rosuvastatin plasma levels were significantly inc concomitant administration of many anti-viral di	
Ciincarnipact.	increases the risk of myopathy and rhabdomyo	
		Avoid
Intervention:	 Sofosbuvir/velpatasvir/voxilaprevir 	concomitant use
intervention.	 Ledipasvir/sofosbuvir 	with
		rosuvastatin.
	Simeprevir	Initiate with
	Dasabuvir/ombitasvir/paritaprevir/ritonavir	
	Elbasvir/grazoprevir	mg once daily,
	 Sofosbuvir/velpatasvir 	and do not
	Glecaprevir/pibrentasvir	exceed a dose of
	 Atazanavir/ritonavir Lopinavir/ritonavir 	rosuvastatin 10
		mg once daily.
Darolutamide	1	<u></u>
	Darolutamide increased rosuvastatin exposure	
Clinical Impact:	The risk of myopathy and rhabdomyolysis is inc	reased with
	concomitant use.	
Intervention:	In patients taking darolutamide, do not exceed a rosuvastatin 5 mg once daily.	a dose of
Regorafenib		
	Regorafenib increased rosuvastatin exposure a	nd may increase
Clinical Impact:	the risk of myopathy.	·····, ·····
Intervention:	In natients taking regoratenih, do not exceed a	dose of
	rosuvastatin 10 mg once dally.	
Fenofibrates (e.g., f	enofibrate and fenofibric acid)	
Clinical Incorrect	Fibrates may cause myopathy when given alone	
Ciinicai Impact:	myopathy and rhabdomyolysis is increased with of fibrates with rosuvastatin.	i concomilant use
	Consider if the benefit of using fibrates concom	itantly with
	rosuvastatin outweighs the increased risk of m	
Intervention	rhabdomyolysis. If concomitant use is decided,	
		- 1

ווונכו עכוונוטוו.	for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.
Niacin	
Clinical Impact:	Cases of myopathy and rhabdomyolysis have occurred with concomitant use of lipid-modifying doses (≥ 1 g/day) of niacin with rosuvastatin.
Intervention:	Consider if the benefit of using lipid-modifying doses (≥ 1 g/day) of niacin concomitantly with rosuvastatin outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.
Colchicine	
Clinical Impact:	Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with rosuvastatin.
Intervention:	Consider if the benefit of using colchicine concomitantly with rosuvastatin outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.

7.2 Drug Interactions that Decrease the Efficacy of Rosuvastatin

Table 6 presents drug interactions that may decrease the efficacy of rosuvastatin and instructions for preventing or managing them.

Table 6: Drug Interactions that Decrease the Efficacy of Rosuvastatin

Antacids	
Clinical Impact:	Concomitant aluminum and magnesium hydroxide combination antacid administration decreased the mean exposure of rosuvastatin 50% [see Clinical Pharmacology (12.3)].
Intervention:	In patients taking antacid, administer rosuvastatin at least 2 hours after the antacid .

7.3 Rosuvastatin Effects on Other Drugs

Table 7 presents rosuvastatin's effect on other drugs and instructions for preventing or managing them.

Warfarin	
Clinical Impact:	Rosuvastatin significantly increased the INR in patients receiving warfarin [see Clinical Pharmacology (12.3)].
Intervention:	In patients taking warfarin, obtain an INR before starting rosuvastatin and frequently enough after initiation, dose titration or discontinuation to ensure that no significant alteration in INR occurs. Once the INR is stable, monitor INR at regularly recommended intervals.

Table 7: Rosuvastatin Effects on Other Drugs

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Discontinue rosuvastatin when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient.

Rosuvastatin decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, rosuvastatin may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients.

Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with rosuvastatin use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage (*see Data*).

In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered rosuvastatin during the period of organogenesis at doses that resulted in systemic exposures equivalent to human exposures at the maximum recommended human dose (MRHD) of 40 mg/day, based on AUC and body surface area (mg/m2), respectively *(see Data)*.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

<u>Data</u>

Human Data

A Medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births.

Animal Data

In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to

gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD dose of 40 mg/day based on AUC).

In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area).

In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18, decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area).

Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. In rabbits, fetal tissue distribution was 25% of maternal plasma concentration after a single oral gavage dose of 1 mg/kg on gestation day 18.

8.2 Lactation

<u>Risk Summary</u>

Limited data from case reports in published literature indicate that rosuvastatin is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Statins, including rosuvastatin, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant.

Because of the potential for serious adverse reactions in a breastfed infant, based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment with rosuvastatin [see Use in Specific Populations (8.1) and Clinical Pharmacology (12.1)].

8.4 Pediatric Use

The safety and effectiveness of rosuvastatin as an adjunct to diet to reduce LDL-C have been established in pediatric patients 8 years of age and older with HeFH. Use of rosuvastatin for this indication is based on one 12-week controlled trial with a 40-week open-label extension period in 176 pediatric patients 10 years of age and older with HeFH and one 2-year open-label, uncontrolled trial in 175 pediatric patients 8 years of age and older with HeFH [see Clinical Studies (14)]. In the 1-year trial with a 12-week controlled phase, there was no detectable effect of rosuvastatin on growth, weight, BMI (body mass index), or sexual maturation in patients aged 10 to 17 years.

The safety and effectiveness of rosuvastatin as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established pediatric patients 7 years of age and older with HoFH. Use of rosuvastatin for this indication is based on a randomized, placebo-controlled, cross-over study in 14 pediatric patients 7 years of age and older with HoFH [see Clinical Studies (14)].

The safety and effectiveness of rosuvastatin have not been established in pediatric patients younger than 8 years of age with HeFH, younger than 7 years of age with HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH).

8.5 Geriatric Use

Of the total number of rosuvastatin-treated patients in clinical studies, 3159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

Advanced age (\geq 65 years) is a risk factor for rosuvastatin-associated myopathy and rhabdomyolysis. Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving rosuvastatin for the increased risk of myopathy [see Warnings and Precautions (5.1)].

8.6 Renal Impairment

Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CLcr \geq 30 mL/min/1.73 m²). Exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal impairment (CLcr <30 mL/min/1.73 m²) who are not receiving hemodialysis [see Clinical Pharmacology (12.3)].

Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. In patients with severe renal impairment not on hemodialysis, the recommended starting dosage is 5 mg daily and should not exceed 10 mg daily [see Dosage and Administration (2.5) and Warnings and Precautions (5.1)].

8.7 Hepatic Impairment

Rosuvastatin is contraindicated in patients with acute liver failure or decompensated cirrhosis. Chronic alcohol liver disease is known to increase rosuvastatin exposure. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Contraindications (4), Warning and Precautions (5.3) and Clinical Pharmacology (12.3)].

8.8 Asian Patients

Pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to rosuvastatin in Asian subjects when compared with White controls. Adjust the rosuvastatin dosage in Asian *patients* [see Dosage and Administration (2.4) and *Clinical Pharmacology* (12.3)].


10 OVERDOSAGE

No specific antidotes for rosuvastatin are known. Hemodialysis does not significantly enhance clearance of rosuvastatin. Contact Poison Control (1-800-222-1222) for latest recommendations.

11 DESCRIPTION

Rosuvastatin calcium USP is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)reductase inhibitor.

The chemical name for rosuvastatin calcium USP is bis[(E)-7-[4-(4-fluorophenyl)-6isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6enoic acid] calcium salt with the following structural formula:



The empirical formula for rosuvastatin calcium USP is $(C_{22}H_{27}FN_3O_6S)_2Ca$ and the molecular weight is 1001.14. Rosuvastatin calcium is a white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 0.13 at pH of 7.0.

Rosuvastatin tablets USP for oral administration contain 5 mg, 10 mg, 20 mg, or 40 mg (equivalent to 5.2 mg, 10.4 mg, 20.8 mg, and 41.6 mg rosuvastatin calcium) and the following inactive ingredients: Each tablet contains: crospovidone, dibasic calcium phosphate dihydrate, iron oxide yellow, iron oxide red, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Rosuvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.

12.2 Pharmacodynamics

Inhibition of HMG-CoA reductase by rosuvastatin accelerates the expression of LDLreceptors, followed by the uptake of LDL-C from blood to the liver, leading to a decrease in plasma LDL-C and total cholesterol. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very-low-density lipoproteins. The maximum LDL-C reduction of rosuvastatin is usually achieved by 4 weeks and is maintained after that.

12.3 Pharmacokinetics

<u>Absorption</u>

In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both C_{max} and AUC increased in approximate proportion to rosuvastatin dose. The absolute bioavailability of rosuvastatin is approximately 20%. The AUC of rosuvastatin does not differ following evening or morning drug administration.

Effect of food

Administration of rosuvastatin with food did not affect the AUC of rosuvastatin.

Distribution

Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.

Elimination

Metabolism

Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \ 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound.

Excretion

Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route. The elimination half-life of rosuvastatin is approximately 19 hours.

Specific Populations

Geriatric Patients

There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age \geq 65 years).

Pediatric Patients

In a population pharmacokinetic analysis of two pediatric trials involving patients with heterozygous familial hypercholesterolemia 10 to 17 years of age and 8 to 17 years of age, respectively, rosuvastatin exposure appeared comparable to or lower than rosuvastatin exposure in adult patients.

Male and Female Patients

There were no differences in plasma concentrations of rosuvastatin between men and women.

Racial or Ethnic Groups

A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2-fold elevation in median exposure (AUC and C_{max}) in Asian subjects when compared with a Caucasian control group.

Patients with Renal Impairment

Mild to moderate renal impairment (CLcr \geq 30 mL/min/1.73 m2) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3-fold) in patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) not receiving hemodialysis compared with healthy subjects (CLcr >80 mL/min/1.73 m2). Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.

Patients with Hepatic Impairment

In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.

In patients with Child-Pugh A disease, C_{max} and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child-Pugh B disease, C_{max} and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.

Drug Interactions Studies

Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.

Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration of rosuvastatin with medications that are inhibitors of these transporter proteins (e.g. cyclosporine, certain HIV protease inhibitors) may result in increased rosuvastatin plasma *concentrations* [see Dosage and Administration (2.6) and Drug Interactions (7.1)].

Coadministered drug and dosing regimen	Rosuvastatin			
		Mean Ratio (ratio with/without coadministered drug) No Effect=1.0		
	Dose (mg)*	Change in AUC	Change in C _{max}	
Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days	10 mg, single dose	7.39 [†] (6.68-8.18) [‡]	18.88 (16.23-21.96)	
Cyclosporine – stable dose required (75 mg – 200 mg BID)	10 mg, QD for 10 days	7.1	11	
Darolutamide 600 mg BID, 5 days	5 mg, single dose	5.2	~5	
Regorafenib 160 mg QD, 14 days	5 mg, single dose	3.8	4.6	
Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days	10 mg	3.1	7	
Simeprevir 150 mg QD, 7 days	10 mg, single dose	2.8 (2.3-3.4)	3.2 (2.6-3.9)	
Velpatasvir 100 mg once daily	10 mg, single dose	2.69 (2.46-2.94)	2.61 (2.32-2.92)	
Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg + dasabuvir	5 mg, single	2.59	7.13	

Table 8: Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure

400 mg BID	UUSE	(2.03-3.21)	(7.11-2.20)
Teriflunomide	Not available	2.51	2.65
Enasidenib 100 mg QD, 28 days	10 mg, single dose	2.44	3.66
Elbasvir 50 mg/grazoprevir 200 mg once daily	10 mg, single dose	2.26 (1.89-2.69)	5.49 (4.29-7.04)
Glecaprevir 400 mg/pibrentasvir 120 mg once daily	5 mg, once daily	2.15 (1.88-2.46)	5.62 (4.80-6.59)
Lopinavir/ritonavir combination	20 mg, QD for	2.1	5
400 mg/100 mg BID for 17 days	7 days	(1.7-2.6)	(3.4-6.4)
Capmatinib 400 mg BID	10 mg, single dose	2.08 (1.56-2.76)	3.04 (2.36-3.92)
Fostamatinib 100 mg BID	20 mg, single dose	1.96 (1.77-2.15)	1.88 (1.69-2.09)
Febuxostat 120 mg OD for 4 days	10 mg, single dose	1.9 (1.5-2.5)	2.1 (1.8-2.6)
Gemfibrozil 600 mg BID for 7 days	80 mg	1.9 (1.6-2.2)	2.2 (1.8-2.7)
Tafamidis 61 mg QD, BID on Days 1 & 2, followed by QD on Days 3 to 9	10 mg	1.97 (1.68-2.31)	1.86 (1.59-2.16)
Eltrombopag 75 mg QD, 5 days	10 mg	1.6 (1.4-1.7)	2 (1.8-2.3)
Darunavir 600 mg/ritonavir 100 mg	10 mg, QD for 7	1.5	2.4
BID, 7 days	days	(1.0-2.1)	(1.6-3.6)
Tipranavir/ritonavir combination	10 mg	1.4	2.2
500 mg/200 mg BID for 11 days	_	(1.2-1.6)	(1.8-2.7)
Dronedarone 400 mg BID	10 mg	1.4	
Itraconazole 200 mg QD, 5 days	10 mg or 80 mg	$ \begin{array}{r} 1.4 \\ (1.2-1.6) \\ 1.3 \\ (1,1,1,4) \end{array} $	$ \begin{array}{r} 1.4 \\ (1.2-1.5) \\ 1.2 \\ (0.0, 1, 4) \end{array} $
Fratissika 10 mar OD 14 days		(1.1-1.4)	(0.9-1.4)
Ezetimibe 10 mg QD, 14 days	10 mg, QD for 14 days	1.2 (0.9-1.6)	1.2 (0.8-1.6)
Fosamprenavir/ritonavir 700 mg/100 mg BID for 7 days	10 mg	1.1	1.5
Fenofibrate 67 mg TID for 7 days	10 mg	↔	1.2 (1.1-1.3)
Rifampicin 450 mg QD, 7 days Aluminum & magnesium hydroxide	20 mg	↔ 0.5	0.5
combination antacid	40 mg	(0.4-0.5)	(0.4-0.6)
Administered simultaneously	40 mg	0.8	0.8
Administered 2 hours apart		(0.7-0.9)	(0.7-1.0)
Ketoconazole 200 mg BID for 7 days	80 mg	1.0 (0.8-1.2)	1.0 (0.7-1.3)
Fluconazole 200 mg QD for 11 days	80 mg	1.1 (1.0-1.3)	1.1 (0.9-1.4)
Erythromycin 500 mg QID for 7 days	80 mg	0.8 (0.7-0.9)	0.7 (0.5-0.9)
QD= Once daily, BID= Twice daily, TID	= Three times da		

* Single dose unless otherwise noted.

+ Clinically significant [see Dosage and Administration (2) and Warnings and Precautions (5)]

 \ddagger Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30%

decrease, 11=11-fold increase in exposure)

Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure toOther Drugs

Rosuvastatin Dosage Regimen	Coadministered Drug					
		Mean Ratio (ratio with/ coadministe No Effect=1	without ered drug)			
	Name and Dose	Change in AUC	Change in C _{max}			
40 mg QD for	Warfarin*	R-Warfarin	R-Warfarin			
10 days	25 mg single dose	1.0	1.0			
		$(1.0-1.1)^{\dagger}$	(0.9-1.0)			
		S-Warfarin	S-Warfarin			
		1.1	1.0			
		(1.0-1.1)	(0.9-1.1)			
40 mg QD for	Digoxin	1.0	1.0			
12 days	0.5 mg single dose	(0.9-1.2)	(0.9-1.2)			
40 mg QD for	Oral Contraceptive	EE 1.3	EE 1.3			
28 days	(ethinyl estradiol 0.035 mg & norgestrel	(1.2-1.3)	(1.2-1.3)			
-	0.180, 0.215 and 0.250 mg) QD for	NG 1.3	NG 1.2			
	21 Days	(1.3 - 1.4)	(1.1-1.3)			

EE = ethinyl estradiol, NG = norgestrel, QD = Once daily

* Clinically significant pharmacodynamic effects [see Drug Interactions (7.3)]

+ Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11-fold increase in exposure)

12.5 Pharmacogenomics

Disposition of rosuvastatin, involves OATP1B1 and other transporter proteins. Higher plasma concentrations of rosuvastatin have been reported in very small groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1 (*SLCO1B1* 521T > C). The frequency of this genotype (i.e., *SLCO1B1* 521 C/C) is generally lower than 5% in most racial/ethnic groups. The impact of this polymorphism on efficacy and/or safety of rosuvastatin has not been clearly established.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses.

In a 107-week carcinogenicity study in mice given 10, 60, or 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times the human exposure at 40 mg/day

based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses.

Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with *Salmonella typhimurium and Escherichia coli*, the mouse lymphoma assay, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the *in vivo* mouse micronucleus test.

In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 50 mg/kg/day (systemic exposures up to 10 times the human exposure at 40 mg/day based on AUC). In testicles of dogs treated with rosuvastatin at 30 mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells were observed in monkeys after 6-month treatment at 30 mg/kg/day in addition to vacuolation of seminiferous tubular epithelium. Exposures in the dog were 20 times and in the monkey 10 times the human exposure at 40 mg/day based on body surface area. Similar findings have been seen with other drugs in this class.

14 CLINICAL STUDIES


Primary Prevention of Cardiovascular Disease

In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major cardiovascular (CV) disease events was assessed in 17,802 men (\geq 50 years) and women (\geq 60 years) who had no clinically evident cardiovascular disease, LDL-C levels <130 mg/dL and hsCRP levels \geq 2 mg/L. The study population had an estimated baseline coronary heart disease risk of 11.6% over 10 years based on the Framingham risk criteria and included a high percentage of patients with additional risk factors such as hypertension (58%), low HDL-C levels (23%), cigarette smoking (16%), or a family history of premature CHD (12%). Patients had a median baseline LDL-C of 108 mg/dL and hsCRP of 4.3 mg/L. Patients were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years. The JUPITER study was stopped early by the Data Safety Monitoring Board due to meeting predefined stopping rules for efficacy in rosuvastatin-treated subjects.

The primary end point was a composite end point consisting of the time-to-first occurrence of any of the following major CV events: CV death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina or an arterial revascularization procedure.

Rosuvastatin significantly reduced the risk of major CV events (252 events in the placebo group vs. 142 events in the rosuvastatin group) with a statistically significant (p<0.001) relative risk reduction of 44% and absolute risk reduction of 1.2% (see Figure 1). The risk reduction for the primary end point was consistent across the following predefined subgroups: age, sex, race, smoking status, family history of premature CHD, body mass index, LDL-C, HDL-C, and hsCRP levels.

Figure 1. Time to First Occurrence of Major Cardiovascular Events in JUPITER



The individual components of the primary end point are presented in Figure 3. Rosuvastatin significantly reduced the risk of nonfatal myocardial infarction, nonfatal stroke, and arterial revascularization procedures. There were no significant treatment differences between the rosuvastatin and placebo groups for death due to cardiovascular causes or hospitalizations for unstable angina.

Rosuvastatin significantly reduced the risk of myocardial infarction (6 fatal events and 62 nonfatal events in placebo-treated subjects vs. 9 fatal events and 22 nonfatal events in rosuvastatin-treated subjects) and the risk of stroke (6 fatal events and 58 nonfatal events in placebo-treated subjects vs. 3 fatal events and 30 nonfatal events in rosuvastatin-treated subjects).

In a post-hoc subgroup analysis of JUPITER subjects (rosuvastatin=725, placebo=680) with a hsCRP ≥ 2 mg/L and no other traditional risk factors (smoking, BP $\geq 140/90$ or taking antihypertensives, low HDL-C) other than age, after adjustment for high HDL-C, there was no significant treatment benefit with rosuvastatin treatment.

Figure 2. Major CV Events by Treatment Group in JUPITER

Number of events						
End point	Rosuva 20 mg (n=8901) n (rate*)	Placebo 20 mg (n=8901) n (rate*)	HR (95% CI)	P value	Hazard Ratio	(-—95%—-)
Primary end point (MCE)	142 (7.6)	252 (13.6)	0.56 (0.46, 0.69)	<0.001	-•-	
Cardiovascular death**	35 (1.9)	44 (2.4)	0.80 (0.51, 1.24)	0.315	-•	-
Nonfatal Stroke	30 (1.6)	58 (3.1)	0.52 (0.33, 0.80)	0.003		
Nonfatal MI	22 (1.2)	62 (3.3)	0.35 (0.22, 0.58)	<0.001		
Hospitalized unstable Angina	16 (0.9)	27 (1.5)	0.59 (0.32, 1.10)	0.093	-•	
Arterial revascularization	71 (3.8)	131 (7.1)	0.54 (0.41, 0.72)	<0.001		
				(0.1	i

* event rate/1000-patient years

** Cardiovascular death included fatal MI, fatal stroke, sudden death, and other adjudicated causes of CV death

At one year, rosuvastatin increased HDL-C and reduced LDL-C, hsCRP, total cholesterol and serum triglyceride levels (p<0.001 for all versus placebo).

Primary Hyperlipidemia in Adults

Rosuvastatin reduces Total-C, LDL-C, ApoB, non-HDL-C, and TG, and increases HDL-C, in adult patients with hyperlipidemia and mixed dyslipidemia.


In a multicenter, double-blind, placebo-controlled study in patients with hyperlipidemia, rosuvastatin given as a single daily dose (5 to 40 mg) for 6 weeks significantly reduced Total-C, LDL-C, non-HDL-C, and ApoB, across the dose range (Table 10).

Dose	Ν	Total-C	LDL-C	Non-HDL-C	АроВ	TG	HDL-C
Placebo	13	-5	-7	-7	-3	-3	3
Rosuvastatin 5 mg	17	-33	-45	-44	-38	-35	13
Rosuvastatin 10 mg	17	-36	-52	-48	-42	-10	14
Rosuvastatin 20 mg	17	-40	-55	-51	-46	-23	8
Rosuvastatin 40 mg	18	-46	-63	-60	-54	-28	10

Table 10: Lipid-modifying Effect of Rosuvastatin in Adult Patients withHyperlipidemia (Adjusted Mean % Change from Baseline at Week 6)

Rosuvastatin was compared with the statins (atorvastatin, simvastatin, and pravastatin) in a multicenter, open-label, dose-ranging study of 2240 patients with hyperlipidemia or mixed dyslipidemia. After randomization, patients were treated for 6 weeks with a single daily dose of either rosuvastatin, atorvastatin, simvastatin, or pravastatin (Figure 3 and Table 11).

Figure 3. Percent LDL-C Change by Dose of Rosuvastatin, Atorvastatin, Simvastatin, and Pravastatin at Week 6 in Adult Patients with Hyperlipidemia or Mixed Dyslipidemia



Box plots are a representation of the 25th, 50th, and 75th percentile values, with whiskers representing the 10th and 90th percentile values. Mean baseline LDL-C: 189 mg/dL.

Table 11: Percent Change in LDL-C by Dose of Rosuvastatin, Atorvastatin, Simvastatin, and Pravastatin From Baseline to Week 6 (LS Mean^{*}) in Adult Patients with Hyperlipidemia or Mixed Dyslipidemia (Sample Sizes Ranging from 156-167 Patients Per Group)

	Treatment Daily Dose					
Treatment	10 mg	20 mg	40 mg	80 mg		
Rosuvastatin	-46†	-52 [‡]	-55 [§]			
Atorvastatin	-37	-43	-48	-51		
Simvastatin	-28	-35	-39	-46		
Pravastatin	-20	-24	-30			

* Corresponding standard errors are approximately 1.00.

+ Rosuvastatin 10 mg reduced LDL-C significantly more than atorvastatin 10 mg; pravastatin 10 mg, 20 mg, and 40 mg; simvastatin 10 mg, 20 mg, and 40 mg. (p<0.002)</p>

‡ Rosuvastatin 20 mg reduced LDL-C significantly more than atorvastatin 20 mg and 40 mg; pravastatin 20 mg and 40 mg; simvastatin 20 mg, 40 mg, and 80 mg. (p<0.002)</p>

§ Rosuvastatin 40 mg reduced LDL-C significantly more than atorvastatin 40 mg; pravastatin 40 mg; simvastatin 40 mg, and 80 mg. (p<0.002)</p>

Slowing of the Progression of Atherosclerosis

In the Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR) study, the effect of therapy with rosuvastatin on carotid atherosclerosis was assessed by B-mode ultrasonography in patients with elevated LDL-C, at low risk (Framingham risk <10% over ten years) for symptomatic coronary artery disease and with subclinical atherosclerosis as evidenced by carotid intimal-medial thickness (cIMT). In this double-blind, placebo-controlled clinical study 984 adult patients were randomized (of whom 876 were analyzed) in a 5:2 ratio to rosuvastatin 40 mg or placebo once daily. Ultrasonograms of the carotid walls were used to determine the annualized rate of change per patient from baseline to two years in mean maximum cIMT of 12 measured segments. The estimated difference in the rate of change in the maximum cIMT analyzed over all 12 carotid artery sites between patients treated with rosuvastatin and placebo-treated patients was -0.0145 mm/year (95% CI -0.0196, -0.0093; p<0.0001).

The annualized rate of change from baseline for the placebo group was +0.0131 mm/year (p<0.0001). The annualized rate of change from baseline for the group treated with rosuvastatin was -0.0014 mm/year (p=0.32).

At an individual patient level in the group treated with rosuvastatin, 52.1% of patients demonstrated an absence of disease progression (defined as a negative annualized rate of change), compared to 37.7% of patients in the placebo group.

HeFH in Adults

In a study of adult patients with HeFH (baseline mean LDL of 291 mg/dL), patients were randomized to rosuvastatin 20 mg or atorvastatin 20 mg. The dose was increased at 6-week intervals. Significant LDL-C reductions from baseline were seen at each dose in both treatment groups (Table 12).

			Atorvastatin (n=187) LS Mean ¹ (95% CI)
Week 6	20 mg	-47% (-49%, -46%)	-38% (-40%, -36%)
Week 12	40 mg	-55% (-57%, -54%)	-47% (-49%, -45%)
Week 18	80 mg	NA	-52% (-54%, -50%)

* LS Means are least square means adjusted for baseline LDL-C

HeFH in Pediatric Patients

In a double-blind, randomized, multicenter, placebo-controlled, 12-week study, 176 (97

male and 79 female) children and adolescents with heterozygous familial hypercholesterolemia were randomized to rosuvastatin 5 mg, 10 mg or 20 mg or placebo daily. Patients ranged in age from 10 to 17 years (median age of 14 years) with approximately 30% of the patients 10 to 13 years and approximately 17%, 18%, 40%, and 25% at Tanner stages II, III, IV, and V, respectively. Females were at least 1 year postmenarche. Mean LDL-C at baseline was 233 mg/dL (range of 129 to 399). The 12-week double-blind phase was followed by a 40 week open label dose-titration phase, where all patients (n=173) received 5 mg, 10 mg or 20 mg rosuvastatin daily.

Rosuvastatin significantly reduced LDL-C (primary end point), total cholesterol and ApoB levels at each dose compared to placebo. Results are shown in Table 13 below.

Table 13: Lipid-Modifying Effects of Rosuvastatin in Pediatric Patients 10 to17 years of Age with Heterozygous Familial Hypercholesterolemia (Least-
Squares Mean Percent Change from Baseline To Week 12)

Dose (mg)	Ν	LDL-C	HDL-C	Total-C	TG*	АроВ
Placebo	46	-1%	+7%	0%	-7%	-2%
5	42	-38%	+4%†	-30%	-13%	-32%
10	44	-45%	+11%	-34%	-15%	-38%
20	44	-50%	+9%	-39%	16%	-41%

* Median percent change

† Difference from placebo not statistically significant

Rosuvastatin was also studied in a two-year open-label, uncontrolled, titration-to-goal trial that included 175 children and adolescents with heterozygous familial hypercholesterolemia who were 8 to 17 years old (79 boys and 96 girls). All patients had a documented genetic defect in the LDL receptor or in ApoB. Approximately 89% were White, 7% were Asian, 1% were Black, and fewer than 1% were Hispanic. Mean LDL-C at baseline was 236 mg/dL. Fifty-eight (33%) patients were prepubertal at baseline. The starting rosuvastatin dosage for all children and adolescents was 5 mg once daily. Children 8 to less than 10 years of age (n=41 at baseline) could titrate to a maximum dosage of 10 mg once daily, and children and adolescents 10 to 17 years of age could titrate to a maximum dosage of 20 mg once daily.

The reductions in LDL-C from baseline were generally consistent across age groups within the trial as well as with previous experience in both adult and pediatric controlled trials.

HoFH in Adult and Pediatric Patients

In an open-label, forced-titration study, HoFH patients (n=40, 8-63 years) were evaluated for their response to rosuvastatin 20 to 40 mg titrated at a 6-week interval. In the overall population, the mean LDL-C reduction from baseline was 22%. About onethird of the patients benefited from increasing their dose from 20 mg to 40 mg with further LDL-C lowering of greater than 6%. In the 27 patients with at least a 15% reduction in LDL-C, the mean LDL-C reduction was 30% (median 28% reduction). Among 13 patients with an LDL-C reduction of <15%, 3 had no change or an increase in LDL-C. Reductions in LDL-C of 15% or greater were observed in 3 of 5 patients with known receptor negative status.

HoFH in Pediatric Patients

Rosuvastatin was studied in a randomized, double-blind, placebo-controlled, multicenter, cross-over study in 14 pediatric patients with HoFH. The study included a 4-week dietary lead-in phase during which patients received rosuvastatin 10 mg daily, a cross-over

phase that included two 6-week treatment periods with either rosuvastatin 20 mg or placebo in random order, followed by a 12-week open-label phase during which all patients received rosuvastatin 20 mg. Patients ranged in age from 7 to 15 years of age (median 11 years), 50% were male, 71% were White, 21% were Asian, 7% were Black, and no patients were of Hispanic ethnicity. Fifty percent were on apheresis therapy and 57% were taking ezetimibe. Patients who entered the study on apheresis therapy or ezetimibe continued the treatment throughout the entire study. Mean LDL-C at baseline was 416 mg/dL (range 152 to 716 mg/dL). A total of 13 patients completed both treatment periods of the randomized cross-over phase; one patient withdrew consent due to inability to have blood drawn during the cross-over phase.

Rosuvastatin 20 mg significantly reduced LDL-C, total cholesterol, ApoB, and non-HDL-C compared to placebo (Table 14).

Table 14: Lipid-modifying Effects of Rosuvastatin in Pediatric Patients 7 to 15
years of Age with Homozygous Familial Hypercholesterolemia After 6 Weeks

	Placebo (N=13)	Rosuvastatin 20 mg (N=13)	Percent difference (95% CI)
LDL-C (mg/dL)	481	396	-22.3% (-33.5, -9.1)*
Total-C (mg/dL)	539	448	-20.1% (-29.7, -9.1) [†]
Non-HDL-C (mg/dL)	505	412	-22.9% (-33.7, -10.3)
ApoB (mg/dL)	268	235	-17.1% (-29.2, -2.9) [‡]

% Difference estimates are based on transformations of the estimated mean difference in log LDL measurements between rosuvastatin and placebo using a mixed model adjusted for study period.

* p=0.005

+ p=0.003

‡ p=0.024

Primary Dysbetalipoproteinemia in Adults

In a randomized, multicenter, double-blind crossover study, 32 adult patients (27 with $\epsilon 2/\epsilon^2$ and 4 with apo E mutation [Arg145Cys] with primary dysbetalipoproteinemia entered a 6-week dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet. Following dietary lead-in, patients were randomized to a sequence of treatments for 6 weeks each: rosuvastatin 10 mg followed by rosuvastatin 20 mg or rosuvastatin 20 mg followed by rosuvastatin 10 mg. Rosuvastatin reduced non-HDL-C (primary end point) and circulating remnant lipoprotein levels. Results are shown in the table below.

Table 15: Lipid-modifying Effects of Rosuvastatin 10 mg and 20 mg in Adult Patients with Primary Dysbetalipoproteinemia (Type III hyperlipoproteinemia) After Six Weeks by Median Percent Change (95% CI) from Baseline (N=32)

	Median at Baseline (mg/dL)	Median percent change from baseline (95% CI) rosuvastatin 10 mg	Median percent change from baseline (95% CI) rosuvastatin 20 mg
Total-C	342.5	-43.3	-47.6
		(-46.9, - 37.5)	(-51.6,-42.8)
Triglycerides	503.5	-40.1	-43.0
		(-44.9, -33.6)	(-52.5, -33.1)
Non-HDL-C	294.5	-48.2	-56.4

		(-56.7, -45.6)	(-61.4, -48.5)
VLDL-C + IDL-C	209.5	-46.8	-56.2
		(-53.7, -39.4)	(-67.7, -43.7)
LDL-C	112.5	-54.4	-57.3
		(-59.1, -47.3)	(-59.4, -52.1)
HDL-C	35.5	10.2	11.2
		(1.9, 12.3)	(8.3, 20.5)
RLP-C	82.0	-56.4	-64.9
		(-67.1, -49.0)	(-74.0, -56.6)
Аро-Е	16.0	-42.9	-42.5
-		(-46.3, -33.3)	(-47.1, -35.6)

Hypertriglyceridemia in Adults

In a double-blind, placebo-controlled study in adult patients with baseline TG levels from 273 to 817 mg/dL, rosuvastatin given as a single daily dose (5 to 40 mg) over 6 weeks significantly reduced serum TG levels (Table 16).

Table 16: Lipid-Modifying Effect of Rosuvastatin in Adult Patients with Primary Hypertriglyceridemia After Six Weeks by Median (Min, Max) Percent Change from Baseline to Week 6

Dose	Placebo (n=26)	Rosuvastatin 5 mg (n=25)	Rosuvastatin 10 mg (n=23)	Rosuvastatin 20 mg (n=27)	Rosuvastatin 40 mg (n=25)
Triglycerides	1 (-40, 72)	-21 (-58, 38)	-37 (-65, 5)	-37 (-72, 11)	-43 (-80, -7)
Non-HDL-C	2 (-13, 19)	-29 (-43, -8)	-49 (-59, -20)	-43 (-74, 12)	-51 (-62, -6)
Total-C	1 (-13, 17)	-24 (-40, -4)	-40 (-51, -14)	-34 (-61, -11)	-40 (-51, -4)
LDL-C	5 (-30, 52)	-28 (-71, 2)	-45 (-59, 7)	-31 (-66, 34)	-43 (-61, -3)
HDL-C	-3 (-25, 18)	3 (-38, 33)	8 (-8, 24)	22 (-5, 50)	17 (-14, 63)

16 HOW SUPPLIED/STORAGE AND HANDLING

Rosuvastatin tablets USP are supplied as:

Manufacturer:Recipharm Pharmaservices Private Limited

NDC 70377-006-11: 5 mg. Yellow, round, biconvex, film-coated tablets, debossed with '5' on one side and 'B' on other side; bottle of 30 tablets

NDC 70377-006-12: 5 mg. Yellow, round, biconvex, film-coated tablets, debossed with '5' on one side and 'B' on other side; bottle of 90 tablets

NDC 70377-006-13: 5 mg. Yellow, round, biconvex, film-coated tablets, debossed with '5' on one side and 'B' on other side; bottle of 500 tablets

NDC 70377-007-11: 10 mg. Pink, round, biconvex, film-coated tablets, debossed

Manufacturer:Biocon Pharma Limited

NDC 70377-006-11: 5 mg. Yellow, round, biconvex, film-coated tablets, debossed with '5' on one side and 'B' on other side; bottle of 30 tablets

NDC 70377-006-12: 5 mg. Yellow, round, biconvex, film-coated tablets, debossed with '5' on one side and 'B' on other side; bottle of 90 tablets

NDC 70377-006-15: 5 mg. Yellow, round, biconvex, film-coated tablets, debossed with '5' on one side and 'B' on other side; bottle of 1000 tablets

NDC 70377-007-11: 10 mg. Pink, round, biconvex, film-coated tablets, debossed with

with '10' on one side and 'B' on other side;	'10' on one side and 'B' on other side; bottle
bottle of 30 tablets	of 30 tablets
NDC 70377-007-12: 10 mg. Pink, round,	NDC 70377-007-12: 10 mg. Pink, round,
biconvex, film-coated tablets, debossed	biconvex, film-coated tablets, debossed with
with '10' on one side and 'B' on other side;	'10' on one side and 'B' on other side; bottle
bottle of 90 tablets	of 90 tablets
NDC 70377-007-13: 10 mg. Pink, round, biconvex, film-coated tablets, debossed with '10' on one side and 'B' on other side; bottle of 500 tablets	NDC 70377-007-15: 10 mg. Pink, round, biconvex, film-coated tablets, debossed with '10' on one side and 'B' on other side; bottle of 1000 tablets
NDC 70377-008-11: 20 mg. Pink, round,	NDC 70377-008-11: 20 mg. Pink, round,
biconvex, film-coated tablets, debossed	biconvex, film-coated tablets, debossed with
with '20' on one side and 'B' on other side;	'20' on one side and 'B' on other side; bottle
bottle of 30 tablets	of 30 tablets
NDC 70377-008-12: 20 mg. Pink, round,	NDC 70377-008-12: 20 mg. Pink, round,
biconvex, film-coated tablets, debossed	biconvex, film-coated tablets, debossed with
with '20' on one side and 'B' on other side;	'20' on one side and 'B' on other side; bottle
bottle of 90 tablets	of 90 tablets
NDC 70377-008-13: 20 mg. Pink, round,	NDC 70377-008-15: 20 mg. Pink, round,
biconvex, film-coated tablets, debossed	biconvex, film-coated tablets, debossed with
with '20' on one side and 'B' on other side;	'20' on one side and 'B' on other side; bottle
bottle of 500 tablets	of 1000 tablets
NDC 70377-009-11: 40 mg. Pink, oval,	NDC 70377-009-11: 40 mg. Pink, oval,
biconvex, film-coated tablets, debossed	biconvex, film-coated tablets, debossed with
with '40' on one side and 'B' on other side;	'40' on one side and 'B' on other side; bottle
bottle of 30 tablets	of 30 tablets
NDC 70377-009-12: 40 mg. Pink, oval,	NDC 70377-009-12: 40 mg. Pink, oval,
biconvex, film-coated tablets, debossed	biconvex, film-coated tablets, debossed with
with '40' on one side and 'B' on other side;	'40' on one side and 'B' on other side; bottle
bottle of 90 tablets	of 90 tablets
NDC 70377-009-13: 40 mg. Pink, oval,	NDC 70377-009-15: 40 mg. Pink, oval,
biconvex, film-coated tablets, debossed	biconvex, film-coated tablets, debossed with
with '40' on one side and 'B' on other side;	'40' on one side and 'B' on other side; bottle
bottle of 500 tablets	of 1000 tablets

Storage

Store at 20° to 25°C (68° to 77°F). [See USP controlled room temperature]. Protect from moisture.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Myopathy and Rhabdomyolysis

Advise patients that rosuvastatin may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [see Warnings and Precautions (5.1), and Drug Interactions (7.1)].

Hepatic Dysfunction

Inform patients that rosuvastatin may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice [see Warnings and Precautions (5.3)].

Increases in HbA1c and Fasting Serum Glucose Levels

Inform patients that increases in HbA1c and fasting serum glucose levels may occur with rosuvastatin. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices [see Warnings and Precautions (5.5)].

Pregnancy

.

Advise pregnant patients and patients who can become pregnant of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if rosuvastatin should be discontinued [see Use in Specific Populations (8.1)].

Lactation

Advise patients that breastfeeding during treatment with rosuvastatin is not recommended [see Use in Specific Populations (8.2)].

Concomitant Use of Antacids

When taking rosuvastatin with an aluminum and magnesium hydroxide combination antacid, the antacid should be taken at least 2 hours after rosuvastatin administration [see Drug Interactions (7.2)].

Missed Doses

If a dose is missed, advise patients not take an extra dose. Just resume the usual schedule [see General Dosage and Administration Information (2.1)].

Manufactured for:

Biocon Pharma Inc.,

Iselin, New Jersey, 08830-3009

United States of America

Manufactured by:

Recipharm Pharmaservices Private Limited,

34th KM, Tumkur Road,

Teppada Begur, Nelamangala Taluk,

Bangalore - 562123, India.

Mfg. Lic. No. KTK/25/460/2001

or

Manufactured by:

Biocon Pharma Limited

Bengaluru, India – 560099

Mfg. Lic. No. KTK/25/664/2017

PATIENT INFORMATION

Rosuvastatin (roe soo" va stat' in) Tablets USP

Read this Patient Information carefully before you start taking rosuvastatin tablets and each time you get a refill. If you have any questions about rosuvastatin tablets, ask your doctor. Only your doctor can determine if rosuvastatin tablets are right for you.

What are rosuvastatin tablets?

Rosuvastatin tablets are prescription medicine that contains a cholesterol-lowering medicine called rosuvastatin.

- Rosuvastatin tablets are used to:
- reduce the risk of stroke, heart attack, and the need for procedures to improve blood flow to the heart called arterial revascularization in adults who do not have known heart disease but do have certain additional risk factors.
- Rosuvastatin tablets are used along with diet to:
- lower the level of low-density lipoprotein (LDL) cholesterol or "bad" cholesterol in adults with primary hyperlipidemia.
- slow the buildup of fatty deposits (plaque) in the walls of blood vessels.
- treat adults and children 8 years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (an inherited condition that causes high levels of LDL).
- along with other cholesterol lowering treatments or alone if such treatments are unavailable in adults and children 7 years of age and older with homozygous familial hypercholesterolemia (an inherited condition that causes high levels of LDL).
- treat adults with a type of high cholesterol called primary dysbetalipoproteinemia (type III hyperlipoproteinemia).
- lower the level of fat in your blood (triglycerides) in adults with hypertriglyceridemia.

The safety and effectiveness of rosuvastatin tablets has not been established in children younger than 8 years of age with heterozygous familial hypercholesterolemia or children younger than 7 years of age with homozygous familial hypercholesterolemia or in children with other types of hyperlipidemias (other than HeFH or HoFH).

Who should not take rosuvastatin tablets?

Do not take rosuvastatin tablets if you:

- have liver problems.
- are allergic to rosuvastatin or any of the ingredients in rosuvastatin tablets. See the end of this leaflet for a complete list of ingredients in rosuvastatin tablets. Symptoms of allergic reactions include rash, itching, hives, and swelling.

What should I tell my doctor before and while taking rosuvastatin tablets? Tell your doctor if you:

- have unexplained muscle aches or weakness.
- have or have had kidney problems.
- have or have had liver problems.
- drink more than 2 glasses of alcohol daily.
- have thyroid problems.
- are 65 years of age or older.
- are of Asian descent.
- are pregnant or think you may be pregnant, or are planning to become pregnant. If you become pregnant while taking rosuvastatin tablets, call your healthcare provider

right away to discuss your rosuvastatin tablets treatment.

• are breastfeeding. Rosuvastatin can pass into your breast milk. Breastfeeding is not recommended while taking rosuvastatin tablets.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking rosuvastatin tablets with certain other medicines may affect each other causing side effects. Rosuvastatin tablets may affect the way other medicines work, and other medicines may affect how rosuvastatin tablets work.

Especially tell your doctor if you take:

- cyclosporine (a medicine for your immune system)
- gemfibrozil (a fibric acid medicine for lowering cholesterol)
- fostamatinib (a medicine used to treat low platelet counts)
- febuxostat (a medicine used to treat and prevent high blood levels of uric acid)
- teriflunomide (a medicine used to treat relapsing remitting multiple sclerosis)
- capmatinib (a medicine for the treatment of non-small cell lung cancer)
- tafamidis (used to treat cardiomyopathy [enlarged and thickened heart muscle])
- darolutamide (a medicine for the treatment of prostate cancer)
- regorafenib (a medicine used to treat cancer of the colon and rectum)
- enasidenib (a medicine used to treat acute myeloid leukemia)
- anti-viral medicines including certain HIV or hepatitis C virus drugs such as:
- lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir
 - combination of
 - sofosbuvir/velpatasvir/voxilaprevir
 - dasabuvir/ombitasvir/paritaprevir/ritonavir
 - elbasvir/grazoprevir
 - sofosbuvir/velpatasvir
 - glecaprevir/pibrentasvir and
 - all other combinations with ledipasvir including ledipasvir/sofosbuvir
- certain anti-fungal medicines (such as itraconazole, ketoconazole and fluconazole)
- coumarin anticoagulants (medicines that prevent blood clots, such as warfarin)
- niacin or nicotinic acid
- fibric acid derivatives (such as fenofibrate)
- colchicine (a medicine used to treat gout)

Ask your doctor or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get new medicine.

How should I take rosuvastatin tablets?

- Take rosuvastatin tablets exactly as your doctor tells you to take it.
- Take rosuvastatin tablets, by mouth, 1 time each day. Swallow the tablet whole.
- Rosuvastatin tablets can be taken at any time of day, with or without food.
- Do not change your dose or stop rosuvastatin tablets without talking to your doctor, even if you are feeling well.
- Your doctor may do blood tests to check your cholesterol levels before and during your treatment with rosuvastatin tablets. Your doctor may change your dose of rosuvastatin tablets if needed.
- Your doctor may start you on a cholesterol lowering diet before giving you rosuvastatin tablets. Stay on this diet when you take rosuvastatin tablets.
- Wait at least 2 hours after taking rosuvastatin tablets to take an antacid that contains a combination of aluminum and magnesium hydroxide.
- If you miss a dose of rosuvastatin tablets, take your next dose at your normal

scheduled time. **Do not take** an extra dose of rosuvastatin tablets.

 If you take too much rosuvastatin tablets or overdose, call your doctor or go to the nearest hospital emergency room right away.

What are the possible side effects of rosuvastatin tablets? Rosuvastatin tablets may cause serious side effects, including:

- Muscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. Tell your doctor right away if:
- you have unexplained muscle pain, tenderness, or weakness, especially if you have a fever or feel more tired than usual, while you take rosuvastatin tablets.
- you have muscle problems that do not go away even after your doctor has told you to stop taking rosuvastatin tablets. Your doctor may do further tests to diagnose the cause of your muscle problems.

Your chances of getting muscle problems are higher if you:

- are taking certain other medicines while you take rosuvastatin tablets
- are 65 years of age or older
- have thyroid problems (hypothyroidism) that are not controlled
- have kidney problems
- are taking higher doses of rosuvastatin tablets
- Liver problems. Your doctor may do blood tests to check your liver before you start taking rosuvastatin tablets and if you have symptoms of liver problems while you take rosuvastatin tablets. Call your doctor right away if you have any of the following symptoms of liver problems:
- feel unusually tired or weak
- loss of appetite
- upper belly pain
- dark urine
- yellowing of your skin or the whites of your eyes
- **Protein and blood in the urine.** Rosuvastatin tablets may cause you to have protein and blood in your urine. If you develop protein or blood in your urine, your doctor may decrease your dose of rosuvastatin tablets.
- Increase in blood sugar (glucose) levels. Rosuvastatin tablets may cause an increase in your blood sugar levels.

The most common side effects may include headache, muscle aches and pains, abdominal pain, weakness, and nausea.

Tell your doctor if you have any side effect that bothers you or that does not go away. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at1-800-FDA-1088.

How should I store rosuvastatin tablets?

- Store rosuvastatin tablets at room temperature, between 68°F to 77°F (20°C to 25°C) and in a dry place.
- Safely throw away medicine that is out of date or no longer needed.

Keep rosuvastatin tablets and all medicines out of the reach of children. General Information about the safe and effective use of rosuvastatin tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rosuvastatin tablets for a condition for which it was not prescribed. Do not give rosuvastatin tablets to other people, even if they have the same medical condition you have. It may harm them.

You can ask your pharmacist or doctor for information about rosuvastatin tablets that is written for health professionals.

What are the Ingredients in rosuvastatin tablets?

Active Ingredient: rosuvastatin as rosuvastatin calcium

Inactive Ingredients in 5 mg, 10 mg, 20 mg, and 40 mg tablets: crospovidone, dibasic calcium phosphate dihydrate, iron oxide yellow, iron oxide red, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin.

Manufactured for:

Biocon Pharma Inc., Iselin, New Jersey, 08830-3009 United States of America Manufactured by: Recipharm Pharmaservices Private Limited, 34th KM, Tumkur Road, Teppada Begur, Nelamangala Taluk, Bangalore – 562123, India. Mfg. Lic. No. KTK/25/460/2001 or **Manufactured by:**

Biocon Pharma Limited Bengaluru, India – 560099 Mfg. Lic. No. KTK/25/664/2017

This Patient Information has been approved by the U.S. Food and Drug Administration Revised: 09/2023

Package/Label Display Panel - 5 mg

NDC 70377-006-12

90 tablets

Rosuvastatin Tablets, USP

5 mg tablets

Rx only

Manufactured for:

Biocon Pharma Inc.,

485 US Highway 1 S,

Suite B305, Iselin,

NJ 08830-3009, USA

Manufactured by:

Recipharm Pharmaservices Private Limited,

34th KM, Tumkur Road,

Teppada Begur, Nelamangala Taluk, Bangalore- 562123, India. Mfg. Lic. No. KTK/25/460/2001 or Biocon Pharma Limited, Special Economic Zone, Plot No.5, Phase IV, Bommasandra - Jigani Link Road, Bommasandra Post, Bengaluru, Karnataka 560099, India Mfg. Lic. No. KTK/25/664/2017 or Varnish free zone



and serialisation prints during Product batch packing

to print the following variable data during batch packing.

SN

GTIN : 0000000000000 : 000000000000000

Package/Label Display Panel - 10 mg NDC 70377-007-12 90 tablets Rosuvastatin Tablets, USP 10 mg tablets Rx only Manufactured for: Biocon Pharma Inc., 485 US Highway 1 S,

Suite B305, Iselin,

NJ 08830-3009, USA

Manufactured by:

Recipharm Pharmaservices Private Limited,

34th KM, Tumkur Road,

Teppada Begur, Nelamangala Taluk,

Bangalore- 562123, India.

Mfg. Lic. No. KTK/25/460/2001

or


Biocon Pharma Limited,

Special Economic Zone, Plot No.5, Phase IV,

Bommasandra - Jigani Link Road, Bommasandra Post,

Bengaluru, Karnataka 560099, India

Mfg. Lic. No. KTK/25/664/2017



or



Space for online batch coding and serialisation prints during Product batch packing


Package/Label Display Panel - 20 mg

NDC 70377-008-12

90 tablets

Rosuvastatin Tablets, USP

20 mg tablets Rx only Manufactured for: Biocon Pharma Inc., 485 US Highway 1 S, Suite B305, Iselin, NJ 08830-3009, USA Manufactured by: Recipharm Pharmaservices Private Limited, 34th KM, Tumkur Road, Teppada Begur, Nelamangala Taluk, Bangalore- 562123, India. Mfg. Lic. No. KTK/25/460/2001 or Biocon Pharma Limited, Special Economic Zone, Plot No.5, Phase IV, Bommasandra - Jigani Link Road, Bommasandra Post, Bengaluru, Karnataka 560099, India Mfg. Lic. No. KTK/25/664/2017





and serialisation prints during Product batch packing

Package/Label Display Panel - 40 mg

NDC 70377-009-12

90 tablets

Rosuvastatin Tablets, USP

40 mg tablets

Rx only

Manufactured for:

Biocon Pharma Inc.,

485 US Highway 1 S,

Suite B305, Iselin,

NJ 08830-3009, USA

Manufactured by:

Recipharm Pharmaservices Private Limited,

34th KM, Tumkur Road,

Teppada Begur, Nelamangala Taluk,

Bangalore- 562123, India.

Mfg. Lic. No. KTK/25/460/2001


or

Biocon Pharma Limited,

Special Economic Zone, Plot No.5, Phase IV,

Bommasandra - Jigani Link Road, Bommasandra Post,

Bengaluru, Karnataka 560099, India



or

\$Biocon N	DC 70377- 009 -12	Each film-coated tablet contains rosuvastatin calcium USP equivalent to 40 mg of rosuvastatin.	00912	Manufactured for: Manufactured by: Biocon Pharma Inc, Biocon Pharma Limited, ISELIN, NJ 08830-3009 USA Bengaluru, INDIA, Product of India Mfg.Lic.No.KTK/25/664/2017 Issue. 12/2019 BPLxxxx/xx
Rosuva Tablet 40 mg		USUAL DOSAGE: See accompanying Prescribing Information. WARNING: As with all medications, keep out of the reach of children. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].	M 10377	Unvarnished Area 62 x 32 mm
Rx Only	90 Tablets	Protect from moisture.		

Space for online batch coding and serialisation prints during Product batch packing

ROSUVASTATIN CALCIUM rosuvastatin calcium tablet, film coated					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70377-006		
Route of Administration	ORAL				

Active In	ngred	ient	Active Moiety					
Ingredient Name						Basis Streng		Strength
ROSUVAST UNII:413KH5	TATIN CALCIUM (UNII: 83MVU38M7Q) (ROSUVASTATIN - I5ZJ73)					ROSUVASTAT	IN	5 mg
Inactive	Ingre	edie	nts					
			Ingredient Name				St	trength
			SPHATE DIHYDRATE (UNII: 07TSZ9	7GEP)				
			YSTALLINE (UNII: OP1R32D61U)					
			ATE (UNII: EWQ57Q8I5X)					
			2S7830E561)					
			E (UNII: 70097M6I30)					
			(15 MPA.S) (UNII: 36SFW2JZ 0W) II: 15FIX9V2JP)					
TRIACETIN			-					
			II: 1K09F3G675)					
		-	(UNII: EX43802MRT)					
Product	Chara	acte	ristics					
Color			YELLOW	Score			no scor	e
Shape			ROUND (biconvex)	Size			7mm	
Flavor				Imprin	nt Code	5;B		
Contains								
Packagi	ng							
# Item C	Code		Package Description			ing Start ate		ting End ate
1 NDC:703 006-11		Produ			10/51/2010	6		
2 NDC:703 006-12		Produ		mbinatio	n 10/31/201	6		
3 NDC:703 006-13		Comb	n 1 BOTTLE, PLASTIC; Type 0: Not a bination Product		10/31/2016			
4 NDC:703 006-15	4 NDC:70377- 006-15 1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 09/27/2019							
Market	ting	Inf	ormation					
Marke Categ			Application Number or Monog Citation	raph		ng Start Ite		ting End ate
ANDA		A	NDA207752		10/31/2016			

ROSUVASTATIN CALCIUM

rosuvastatin calcium tablet, film coated

Ro	oduct Type		HUMAN PRESCRIPTION DRUG	G I	tem Code	(Source)	NDC:	70377-007
	ute of Admir	nistration	ORAL					
Ac	tive Ingred	lient/Active	Moiety					
		Ing	redient Name			Basis Stren		Strength
	SUVASTATIN (I:413KH5ZJ73)	CALCIUM (UNII:	83MVU38M7Q) (ROSUVASTAT	IN -		ROSUVASTA	TIN	10 mg
_								
Ina	active Ingr	edients	Ingradiant Nama					Strongth
DIF			Ingredient Name DIHYDRATE (UNII: 07TSZ97	GEP)				Strength
			IE (UNII: OP1R32D61U)	0217				
		HYDRATE (UNII:						
		(UNII: 2S7830E5						
MA	GNESIUM STE	ARATE (UNII: 70	097M6I30)					
HY	PROMELLOSE	2910 (15 MPA	.S) (UNII: 365FW2JZ0W)					
тіт		DE (UNII: 15FIX9)	/2JP)					
TRI	ACETIN (UNII:	XHX3C3X673)						
FEI	RRIC OXIDE RE	D (UNII: 1K09F3	G675)					
FEI	RRIC OXIDE YE	ELLOW (UNII: EX	(43802MRT)					
	lor	PINK		Score			no sco	ore
Sh	аре	ROUND (I	piconvex)	Size			7mm	
Fla	vor			Imprin	t Code		10;B	
Со	ntains							
Da	ckaging							
	Item Code	D	ackage Description		Market	ing Start	Mark	eting End
1	NDC:70377-	30 in 1 BOTTLE	;, PLASTIC; Type 0: Not a Con	nbinatior		ate	l	Date
- 1	007-11 NDC:70377- 007-12		, PLASTIC; Type 0: Not a Con	nbinatior				
2	007-12	Product 10/31/2016 500 in 1 BOTTLE, PLASTIC; Type 0: Not a 10/31/2016						
2	NDC:70377- 007-13				10/31/2010	5		
2 3		Combination Pr	oduct LE, PLASTIC; Type 0: Not a		10/31/2010 09/27/2019			
2 3	007-13 NDC:70377-	Combination Pr 1000 in 1 BOTT	oduct LE, PLASTIC; Type 0: Not a					
2 3 4	007-13 NDC:70377- 007-15	Combination Pr 1000 in 1 BOTT	oduct LE, PLASTIC; Type 0: Not a oduct					
2 3 4	007-13 NDC:70377- 007-15	Combination Pr 1000 in 1 BOTT Combination Pr Informat	oduct LE, PLASTIC; Type 0: Not a oduct	aph	09/27/2019	ng Start		eting End Date

ROSUVASTATIN CALCIUM

FERRIC OXII Product (Color Shape Flavor Contains Packagin # Item Co 1 NDC:7037 008-11 2 NDC:7037 1 NDC:7037 3 NDC:7037 1 NDC	Character Character g ode 7- 30 in Produ 7- 90 in Produ 7- 500 i Com 7- 1000 Com	V (UNII: EXA PINK ROUND (b PINK ROUND (b Pa 1 BOTTLE, uct 1 BOTTLE, uct 1 BOTTLE, in 1 BOTTLE, in 1 BOTTLE bination Pro- bination Pro- ormat	A3802MRT) iconvex) iconvex) PLASTIC; Type PLASTIC; Type E, PLASTIC; Type duct LE, PLASTIC; Type oduct	e 0: Not a Cor e 0: Not a Cor oe 0: Not a ype 0: Not a	mbinatio	Market N 10/31/2016 10/31/2016 10/31/2016 09/27/2019	5	Mark	ore eting End Date eting End Date
Product C Color Shape Flavor Contains Packagine # Item Cc 1 NDC:7037 008-11 2 NDC:7037 3 NDC:7037 4 NDC:7037 008-13 4 NDC:7037	g ode 7- 30 in 7- 30 in 7- 500 i 7- 1000 7- 1000	V (UNII: EXA PINK ROUND (b PA 1 BOTTLE, uct 1 BOTTLE, uct in 1 BOTTLE, in 1 BOTTLE, bination Pro-	A3802MRT) iconvex) iconvex) PLASTIC; Type PLASTIC; Type E, PLASTIC; Type duct LE, PLASTIC; Type oduct	e 0: Not a Cor e 0: Not a Cor e 0: Not a Cor pe 0: Not a	Size Imprir	Market n 10/31/2016 n 10/31/2016	ate 5 5	9mm 20;B	eting End Date
Product C Color Shape Flavor Contains Packagin # Item Cc 1 NDC:7037 008-11 2 NDC:7037 008-12 3 NDC:7037	Be YELLOW Characte G g ode 7- 30 in Prode 7- 90 in Prode 7- 500 i Comi 7- 500 i Comi 7- 1000	V (UNII: EXA PINK ROUND (b PINK ROUND (b 1 BOTTLE, uct 1 BOTTLE, uct 1 BOTTLE, in 1 BOTTLE bination Pro- in 1 BOTTLE	A3802MRT) iconvex) iconvex) PLASTIC; Type PLASTIC; Type E, PLASTIC; Type LE, PLASTIC; Type LE, PLASTIC; Type	e 0: Not a Cor e 0: Not a Cor e 0: Not a Cor pe 0: Not a	Size Imprir	Market n 10/31/2016 n 10/31/2016	ate 5 5	9mm 20;B Marke	eting End
Product C Color Shape Flavor Contains Packagin # Item Cc 1 NDC:7037 008-11 2 NDC:7037 008-12 3 NDC:7037	Be YELLOW Characte G g ode 7- 30 in Prode 7- 90 in Prode 7- 500 i Comi 7- 500 i Comi 7- 1000	V (UNII: EXA PINK ROUND (b PINK ROUND (b 1 BOTTLE, uct 1 BOTTLE, uct 1 BOTTLE, in 1 BOTTLE bination Pro- in 1 BOTTLE	A3802MRT) iconvex) iconvex) PLASTIC; Type PLASTIC; Type E, PLASTIC; Type LE, PLASTIC; Type LE, PLASTIC; Type	e 0: Not a Cor e 0: Not a Cor e 0: Not a Cor pe 0: Not a	Size Imprir	Market n 10/31/2016 n 10/31/2016	ate 5 5	9mm 20;B Marke	eting End
Product C Color Shape Flavor Contains Packaging # Item Cc 1 NDC:7037° 008-11 008-12 3 NDC:7037°	Be YELLOW Characte G g ode 7- 30 in Prode 7- 90 in Prode 7- 500 in Comi	V (UNII: EX4 PINK ROUND (b 1 BOTTLE, uct 1 BOTTLE, uct in 1 BOTTLE bination Pro	A3802MRT) iconvex) iconvex) PLASTIC; Type PLASTIC; Type E, PLASTIC; Type oduct	e 0: Not a Cor e 0: Not a Cor e 0: Not a Cor pe 0: Not a	Size Imprir	Marketi 10/31/2016	ate 5	9mm 20;B Marke	eting End
Product C Color Shape Flavor Contains Packagine # Item Cc 1 NDC:7037 008-11	g ode 7- 30 in Prod	V (UNII: EX4 PINK ROUND (b Pa 1 BOTTLE, uct 1 BOTTLE, uct	43802MRT) iconvex) ckage Desc PLASTIC; Type PLASTIC; Type	e 0: Not a Cor e 0: Not a Cor	Size Imprir	Market Narket	ate ⁶	9mm 20;B Marke	eting End
Product C Color Shape Flavor Contains Packagin # Item Cc 1 NDC:7037 008-11	g pode 7- 30 in Produ	V (UNII: EX4 PINK ROUND (b Pa 1 BOTTLE, uct	43802MRT) iconvex) ickage Deso PLASTIC; Type	e 0: Not a Cor	Size Imprir	Market n 10/31/2016	ate	9mm 20;B Marke	eting End
Product C Color Shape Flavor Contains Packagin	DE YELLOV	V (UNII: EX PINK ROUND (b	438O2MRT) iconvex)	cription	Size	nt Code Market		9mm 20;B Marke	eting End
Product (Color Shape Flavor Contains	DE YELLOV	V (UNII: EXA eristics PINK	43802MRT)		Size	nt Code		9mm 20;B	
Product (Color Shape Flavor	DE YELLOV	V (UNII: EXA eristics PINK	43802MRT)		Size			9mm	ore
Product (Color Shape Flavor	DE YELLOV	V (UNII: EXA eristics PINK	43802MRT)		Size			9mm	ore
Product (Color Shape Flavor	DE YELLOV	V (UNII: EXA eristics PINK	43802MRT)		Size			9mm	ore
Product (DE YELLOV	V (UNII: EXA eristics PINK	43802MRT)		Size			9mm	ore
Product (DE YELLOV	V (UNII: EX			Score			no sco	ore
	DE YELLOV	V (UNII: EX4							
	DE YELLOV	V (UNII: EX4							
FERRIC OXIL									
	DE RED (UN	111. 1100520							
RIACETIN (UNII: XHX30	C3X673)							
TITANIUM D									
			5) (UNII: 36SFV	V2JZ0W)					
MAGNESIUM									
LACTOSE M			EWQ57Q8I5X)						
			E (UNII: OP1R3	2D61U)					
			DIHYDRATE (U		7GEP)				
			Ingredie	nt Name				9	Strength
Inactive I	ngredie	nts							
ROSUVASTA UNII:413KH5Z		UM (UNII: 8	3MVU38M7Q) (ROSUVASTAT	ΓIN -		ROSUVASTAT	ΓΙΝ	20 mg
Ingredient Name Basis of Strength								Strengt	
Active Ing	gredient	Active	Moiety				Deele	- 6	
Route of A	dministra	ation	ORAL						
	vpe		HUMAN PRESC	HUMAN PRESCRIPTION DRUG Item Code (Source				rce) NDC:70377-008	
Product Ty		lion							
	nforma								
	nforma	tion							
osuvastatir Product I Product Ty			ncoaleu						

		CATIN CAL						
03	Suvastatiii Car		Incoated					
Ρ	roduct Info	rmation						
P	roduct Type		HUMAN PRESCRIPTION	DRUG	ltem Code	(Source)	NDC:	70377-009
R	oute of Admir	nistration	ORAL					
A	ctive Ingred	lient/Active	Moiety					
		Ing	redient Name			Basis Streng		Strengt
	SUVASTATIN (III:413KH5ZJ73)	C ALCIUM (UNII: 8	33MVU38M7Q) (ROSUVAS	STATIN -		ROSUVASTAT		40 mg
In	active Ingr	edients						
	active mgr	calento	Ingredient Nam	ie				Strength
ום		M PHOSPHATE	DIHYDRATE (UNII: 07TS					ucingui
			E (UNII: OP1R32D61U)	2576217				
		HYDRATE (UNII:						
		(UNII: 257830E56						
		ARATE (UNII: 70						
		-	S) (UNII: 36SFW2JZOW)					
		DE (UNII: 15FIX9V	-					
	RIACETIN (UNII:		, ,					
		D (UNII: 1K09F3	G675)					
FE	RRIC OXIDE YE	ELLOW (UNII: EX	43802MRT)					
			•					
P	roduct Char	racteristics						
Сс	olor	PINK		Score			no sco	re
Sł	nape	OVAL (bio	convex)	Size	12			
	avor			Imprint	Code		40;B	
	ontains							
Pa	ackaging							
#	ltem Code	Pa	ckage Description	I		Marketing Start I Date		eting End Date
1	NDC:70377- 009-11	30 in 1 BOTTLE, Product	PLASTIC; Type 0: Not a	Combinatio	ⁿ 10/31/2010	6		
2	NDC:70377- 009-12	Product	PLASTIC; Type 0: Not a		ⁿ 10/31/2010	5		
3	NDC:70377- 009-13	Combination Pro		a	10/31/2010	6		
	NDC:70377-	500 in 1 BOTTLE, PLASTIC; Type 0: Not a 10/31/2016 Combination Product 10/00 in 1 BOTTLE, PLASTIC; Type 0: Not a						

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA207752	10/31/2016	

Labeler - Biocon Pharma Inc (080000063)

Registrant - Biocon Limited (650173537)

Establishment

Name	Address	ID/FEI	Business Operations
Recipharm Pharmaservices Private Limited		871401927	manufacture(70377-006, 70377-008, 70377-007, 70377-009)

Establishment

Name	Address	ID/FEI	Business Operations
Biocon Limited		650173537	api manufacture(70377-006, 70377-008, 70377-007, 70377-009)

Establishment

Name	Address	ID/FEI	Business Operations
Biocon Pharma Limited		871412155	manufacture(70377-006, 70377-008, 70377-007, 70377-009)

Revised: 9/2023

Biocon Pharma Inc